Table 2 Leptospirosis prevalence estimates among study population (n = 147) at three enrolling hospitals, Sarawak, Malaysia, according to various diagnostic tests employed. Participants were defined as having leptospirosis if at least two out of three serological tests were found to be positive and/or molecular evidence of Leptospira was identified in either participant sera or urine
From: Leptospirosis infections among hospital patients, Sarawak, Malaysia
Diagnostic type | Kapit Hospital n (%) | Sarikei Hospital n (%) | Sibu Hospital n (%) | Total n (%) |
|---|---|---|---|---|
Sera | ||||
Leptorapide RDT* | 35/102 (34.3) | 12/24 (50.0) | 15/21 (71.4) | 62/147 (42.2) |
MAT† | 2/31 (6.5) | 6/14 (42.3) | 7/14 (50.0) | 15/59 (25.4) |
ELISA assay‡ | 14/102 (13.7) | 3/24 (12.5) | 5/21 (23.8) | 22/147 (15.0) |
qPCR | 16/102 (15.7) | 3/23 (13.0) | 1/21 (4.8) | 20/145 (13.8) |
Urine | ||||
Leptorapide RDT* | 32/100 (32.0) | 4/22 (18.2) | 7/19 (36.8) | 43/141 (30.5) |
qPCR | 19/100 (19.0) | 8/22 (36.4) | 6/19 (31.6) | 33/141 (23.4) |
Leptospirosis-positive participants | 34/102 (33.3) | 9/24 (37.5) | 12/21 (57.1) | 55/147 (37.4) |